CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 46 enrolled
Drug / intervention
bevacizumabbiological
Likely dose
Not stated in record
Key inclusion· 7
  • ✓Histologically confirmed HCC by needle aspirate, biopsy, or prior surgical resection specimen
  • ✓Or clinically confirmed HCC with cirrhosis or chronic hepatitis B/C plus hypervascular masses >2 cm and elevated/rising AFP
  • ✓Deemed unresectable; prior resection allowed; no main portal vein or IVC invasion; no >50% liver volume involvement
  • ✓At least 1 unidimensionally measurable lesion ≥20 mm
Key exclusion· 9
  • ✕Thromboembolic event within past 12 months
  • ✕Clinically significant cardiovascular disease
  • ✕Variceal bleeding within past 6 months
  • ✕Malignancy within past 5 years (except localized nonmelanoma skin cancer)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00055692
NCT00055692Phase 2Completed
CompareCT.gov

Bevacizumab (RhuMAB-VEGF) In Hepatocellular Cancer For Patients With Unresectable Tumor (Without Invasion Of The Main Portal Vein Or Metastatic Disease) A Phase II Study

National Cancer Institute (NCI)·interventional·Posted Mar 7, 2003·Updated Feb 29, 2016

In Brief

A Phase 2 clinical trial evaluating bevacizumab for Adult Primary Hepatocellular Carcinoma and 2 related conditions. Completed, enrolled 46 participants across 1 site.

Detailed Summary

This phase II trial is to see if bevacizumab works in treating patients who have unresectable nonmetastatic liver cancer that has not spread to the main portal vein. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 7, 2003
Enrollment StartFeb 1, 2003
Primary CompletionJan 1, 2008
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 23.3 years ago

Interventions

bevacizumabbiological

Given orally